Callahan Advisors’s GSK GSK Stock Holding History

Callahan Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,875	Closed	-$1.04M	–	168
2024 Q4	$1.04M	Hold	30,875	–	–	0.1%	105
2024 Q3	$1.26M	Hold	30,875	–	–	0.12%	98
2024 Q2	$1.19M	Hold	30,875	–	–	0.12%	95
2024 Q1	$1.32M	Hold	30,875	–	–	0.14%	90
2023 Q4	$1.14M	Hold	30,875	–	–	0.13%	91
2023 Q3	$1.12M	Buy	+30,875	New	+$1.1M	0.14%	87

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Callahan Advisors's GSK Position: Q1 2025 in Review

Callahan Advisors sold out of GSK (GSK) in Q1 2025, closing a stake of 30,875 shares — an estimated $1.04M sold.

Callahan Advisors first reported a position in GSK in Q3 2023 and held it in 6 quarters. The position peaked at $1.32M in Q1 2024. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Callahan Advisors reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
Callahan Advisors sold 30,875 GSK shares in Q1 2025, an estimated $1.04M.
Callahan Advisors first reported a position in GSK in Q3 2023 and held it in 6 quarters.
Callahan Advisors's GSK position peaked at $1.32M in Q1 2024.
857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Callahan Advisors's 13F filing for Q1 2025, filed 1 May 2025.